Theravance Biopharma, Inc.
US ˙ NasdaqGM ˙ KYG8807B1068

SecurityTBPH / Theravance Biopharma, Inc.
InstitutionMacquarie Group Ltd
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Macquarie Group Ltd closes position in TBPH / Theravance Biopharma, Inc.

On February 13, 2026 - Macquarie Group Ltd filed a 13F-HR form disclosing ownership of 0 shares of Theravance Biopharma, Inc. (US:TBPH) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 208,783 shares of Theravance Biopharma, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -100.00 0
2025-11-13 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 3,048 32.35 0.0036
2025-08-14 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 2,303 23.55 0.0028
2025-08-14 2025-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 1,864 -5.14 0.0023
2025-05-15 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 1,864 0.0015
2025-02-14 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 1,965 16.76 0.0024
2024-11-14 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 -709 -0.34 1,683 -5.24 0.0018
2024-08-09 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 209,492 709 0.34 1,776 -5.18 0.0020
2024-05-14 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 1,873 -20.20 0.0021
2024-02-14 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 2,347 30.24 0.0027
2023-11-14 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 1,802 -16.61 0.0023
2023-10-27 2023-06-30 13F/A-2 THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 2,161 -4.59 0.0025
2023-10-12 2023-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 208,783 0 2,161 0.0022
2023-08-14 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 2,161 0.0022
2023-06-01 2023-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 208,783 0 0.00 2,265 -3.33 0.0027
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 0 2,265 0.0021
2023-02-21 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 208,783 -5,296 -2.47 2,343 7.63 0.0028
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 214,079 -633 -0.29 2,177 11.87 0.0027
2022-08-17 2022-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 214,712 0 0.00 1,946 -5.21 0.0022
2022-08-15 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 214,712 0 1,946 0.0007
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 214,712 0 0.00 2,053 -13.49 0.0016
2022-02-11 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 214,712 0 0.00 2,373 49.34 0.0020
2021-11-12 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 214,712 -75,546 -26.03 1,589 -62.30 0.0014
2021-08-13 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 290,258 208,783 256.25 4,215 153.46 0.0035
2021-05-14 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 81,475 11,417 16.30 1,663 33.57 0.0024
2021-02-16 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 70,058 18,675 36.34 1,245 63.82 0.0018
2020-11-13 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 51,383 -1,854 -3.48 760 -31.96 0.0013
2020-08-11 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 53,237 53,237 1,117 0.0019
2016-05-16 2016-03-31 13F THERAVANCE BIOPHARMA COMMON G8807B106 0 -50,000 -100.00 0 -100.00
2016-02-16 2015-12-31 13F THERAVANCE BIOPHARMA COMMON G8807B106 50,000 0 0.00 820 49.09 0.0017
2015-11-16 2015-09-30 13F THERAVANCE BIOPHARMA COMMON G8807B106 50,000 0 0.00 550 -15.51 0.0012
2015-08-21 2015-06-30 13F/A-1 THERAVANCE BIOPHARMA COMMON G8807B106 50,000 0 0.00 651 -25.00 0.0013
2015-08-14 2015-06-30 13F THERAVANCE BIOPHARMA COMMON G8807B106 50,000 651
2015-05-18 2015-03-31 13F THERAVANCE BIOPHARMA COMMON G8807B106 50,000 -27,548 -35.52 868 -24.98 0.0017
2015-02-17 2014-12-31 13F THERAVANCE BIOPHARAM COMMON G8807B106 77,548 77,548 1,157 0.0024
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.